AcelRx Q3 2020 Earnings Report
Key Takeaways
AcelRx Pharmaceuticals reported a net revenue of $1.4 million for the third quarter of 2020, with product sales contributing $1.3 million, a significant increase from the previous quarter. The company's net loss was $8.9 million, or $0.10 per share. Key achievements included a collaboration with Zimmer Biomet and expansion of DSUVIA's availability to the U.S. Department of Defense.
Third quarter product sales reached $1.3 million, a substantial increase from $0.3 million in the second quarter.
Entered into a distribution agreement with Zimmer Biomet to market DSUVIA in the dental and oral surgery markets.
DSUVIA was added to the U.S. Department of Defense Joint Deployment Formulary.
U.S. Army awarded AcelRx with an initial contract of up to $3.6 million over four years for DSUVIA purchase.
AcelRx
AcelRx
Forward Guidance
AcelRx anticipates continued progress within the Department of Defense and expects initial ordering of DSUVIA for deployed troops in the fourth quarter.